/ Print /

Drug costs

Opinion: Top 2 takeaways from UBS Global Healthcare ConferenceThe conference raised important points about unregulated growth opportunities and new pharmacy arena players.
What's missing in hep C drugsPayers have unmet needs in the changing hepatitis C (HCV) space, according to a recent survey. The survey, from Precision for Value, highlights what can be done to encourage payers to ease coverage policies for these drugs in the next wave of HCV treatment.
Five things to know about Trump’s FDA lead pick GottliebOn March 10, the White House announced that President Donald Trump selected Scott Gottlieb, MD, who has worked for FDA in the past, as his choice to head the FDA. Here are five things managed healthcare executives should know about the pick.
Opinion: More industry-stakeholders play blame game for high drug costsOur policy analyst weighs in on a new drug industry PR campaign that attempts to shift the blame for high drug costs.
Payers to pharma: Here’s what we’re missing in hep C drugsA Precision for Value survey highlights what can be done in order to encourage payers to ease coverage policies for these drugs in the next wave of HCV treatment.
Top challenges in cancer careCancer drug costs remain the most critical challenge in care, among other things.
How state-mandated formularies impact costsResearch by Express Scripts presented at the AMCP examines costs among Medicaid members in the Florida plan to members in a similar Medicaid plan without a state-mandated formulary.
Copay assistance programs: Managed care pros and consDo copay assistance program offer a long-term solution for patients? Experts weigh in.
Three ways to rein in drug costs regardless of who becomes presidentIt’s time for stakeholders to cooperate in order to limit the wasted spending on prescription medications and chart a path to collectively improving value derivation.
Drug pipeline developments: Alopecia areata and atopic dermatitisPromising treatments are coming for alopecia areata and atopic dermatitis, but they will come at a high cost.